Found: 27
Select item for more details and to access through your institution.
Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Effect of growth hormone(GH)treatment on adult height in patients with GH deficiency:the Japanese cohort from the GeNeSIS observational study.
- Published in:
- Journal of Japanese Association for Human Auxology, 2020, v. 26, n. 1, p. 28
- By:
- Publication type:
- Article
Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J‐mono study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 126, doi. 10.1111/dom.15296
- By:
- Publication type:
- Article
Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy).
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 398, doi. 10.1111/dom.14882
- By:
- Publication type:
- Article
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 239, doi. 10.1111/dom.14572
- By:
- Publication type:
- Article
The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 12, p. 1279, doi. 10.1111/dom.12758
- By:
- Publication type:
- Article
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 3, p. 649, doi. 10.1007/s13300-024-01534-5
- By:
- Publication type:
- Article
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 12, p. 2173, doi. 10.1007/s13300-023-01485-3
- By:
- Publication type:
- Article
Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 3, p. 735, doi. 10.1007/s13300-020-00765-6
- By:
- Publication type:
- Article
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 133, doi. 10.1007/s13300-019-00726-8
- By:
- Publication type:
- Article
Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 3, p. 1019, doi. 10.1007/s13300-019-0605-7
- By:
- Publication type:
- Article
742-P: Phase 1 Study of Safety, Tolerability, PK, and PD of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with T2DM.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-742-P
- By:
- Publication type:
- Article
969-P: Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-969-P
- By:
- Publication type:
- Article
20-OR: GPR142 Agonists Increase Glucose-Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-20-OR
- By:
- Publication type:
- Article
1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1024-P
- By:
- Publication type:
- Article
Sample size calculations for controlling the distribution of false discovery proportion in microarray experiments.
- Published in:
- Biostatistics, 2009, v. 10, n. 4, p. 694, doi. 10.1093/biostatistics/kxp024
- By:
- Publication type:
- Article
Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 1, p. 383, doi. 10.1007/s13300-017-0346-4
- By:
- Publication type:
- Article
Sample sizes for a robust ranking and selection of genes in microarray experiments.
- Published in:
- Statistics in Medicine, 2009, v. 28, n. 22, p. 2801, doi. 10.1002/sim.3666
- By:
- Publication type:
- Article
Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog<sup>®</sup> in Japanese patients with type 1 diabetes.
- Published in:
- Journal of Diabetes Investigation, 2020, v. 11, n. 3, p. 672, doi. 10.1111/jdi.13195
- By:
- Publication type:
- Article
Cancer Outlier Analysis Based on Mixture Modeling of Gene Expression Data.
- Published in:
- Computational & Mathematical Methods in Medicine, 2013, p. 1, doi. 10.1155/2013/693901
- By:
- Publication type:
- Article
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
- Published in:
- International Journal of Cancer, 2012, v. 130, n. 1, p. 20, doi. 10.1002/ijc.25961
- By:
- Publication type:
- Article
Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
- Published in:
- Endocrine Journal, 2017, v. 64, n. 12, p. 1165, doi. 10.1507/endocrj.ej17-0189
- By:
- Publication type:
- Article
Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
- Published in:
- Endocrine Journal, 2017, v. 64, n. 5, p. 553, doi. 10.1507/endocrj.ej16-0552
- By:
- Publication type:
- Article
Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
- Published in:
- Endocrine Journal, 2017, v. 64, n. 2, p. 191, doi. 10.1507/endocrj.ej16-0365
- By:
- Publication type:
- Article
Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
- Published in:
- Endocrine Journal, 2016, v. 63, n. 3, p. 263, doi. 10.1507/endocrj.ej15-0518
- By:
- Publication type:
- Article
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
- Published in:
- Endocrine Journal, 2015, v. 62, n. 12, p. 1101, doi. 10.1507/endocrj.ej15-0401
- By:
- Publication type:
- Article
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling Matsumura et al.
- Published in:
- Cancer Science, 2010, v. 101, n. 12, p. 2658, doi. 10.1111/j.1349-7006.2010.01736.x
- By:
- Publication type:
- Article